Review
Version 1
Preserved in Portico This version is not peer-reviewed
Medulloblastoma: From TP53 Mutations to Molecular Classification and Liquid Biopsy
Version 1
: Received: 15 December 2022 / Approved: 16 December 2022 / Online: 16 December 2022 (08:47:35 CET)
A peer-reviewed article of this Preprint also exists.
Eibl, R.H.; Schneemann, M. Medulloblastoma: From TP53 Mutations to Molecular Classification and Liquid Biopsy. Biology 2023, 12, 267. Eibl, R.H.; Schneemann, M. Medulloblastoma: From TP53 Mutations to Molecular Classification and Liquid Biopsy. Biology 2023, 12, 267.
Abstract
A recent paradigm shift in diagnostics of medulloblastoma allows the distinction of four major groups defined by genetic data rather than histology. This new molecular classification correlates better with prognosis and will allow better clinical management for therapies targeting druggable mutations, but also offers a new combination of monitoring tumor development in real-time and treatment response by sequential liquid biopsy. This review highlights recent developments after a century of milestones in neurosurgery, radio- and chemotherapy, but also controversial theories on the cell of origin, animal models and the use of liquid biopsy.
Keywords
medulloblastoma; TP53 mutation; molecular classification; diagnostics; liquid biopsy; animal models; transcriptome; precision oncology
Subject
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment